BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240515
DTEND;VALUE=DATE:20240517
DTSTAMP:20260515T222051
CREATED:20240208T131147Z
LAST-MODIFIED:20240208T131147Z
UID:38664-1715731200-1715903999@www.pharmajournalist.com
SUMMARY:GLP-1-Based Therapeutics Summit
DESCRIPTION:The GLP-1-Based Therapeutics Summit is the Ultimate Industry Forum for Developers of GLP-1-Based Therapeutics Across Different Indications \nThe GLP-1-Based Therapeutics Summit is a once-a-year event\, uniting 60+ industry experts to help advance more specialized\, durable\, and efficacious GLP-1s while investigating commercial opportunities to crystallize pipeline strategy and indication expansion. \nGrab your copy of the full agenda \nAmidst the resounding success of Novo’s SELECT trial\, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments\, propelling GLP-1 players to the forefront of pharmaceutical revenue growth. \nIf you are looking to differentiate your GLP-1 products\, forge new relationships with fellow GLP-1 developers\, or discover the newest innovations in improving the tolerability\, efficacy\, and durability of GLP-1s\, there has never been a more appropriate time to unite and navigate this rapidly evolving space at the GLP-1-Based Therapeutics Summit this May! \nKey Highlights: \nUnraveling Exciting Opportunities to Apply GLP-1 Receptor Agonists Across a Wide Range of Indications\nIncluding cardiovascular\, renal\, obstructive sleep apnea\, MASH\, and neurodegenerative diseases with Eli Lily\, D&D Pharmatech\, and Altimmune \nOptimizing the Efficacy of GLP-1-Based Therapeutics\nHear the newest innovations raising the benchmark for more successful weight loss with Diasome Pharmaceuticals and BioAge Labs \nDeveloping a Robust Commercial Strategy \nDifferentiate your GLP-1 products from your competitors\, to effectively target specific patient segments with Altimmune and Regor Therapeutics
URL:http://www.pharmajournalist.com/event/glp-1-based-therapeutics-summit/
LOCATION:Hilton Philadelphia City Avenue\, 4200 City Ave\, Philadelphia\, PA\, 19131\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR